| For: | Economos H, MacIsaac RJ. Cardio-kidney-metabolic protective effects of semaglutide across the spectrum of chronic kidney disease. World J Nephrol 2025; 14(4): 109457 [PMID: 41479840 DOI: 10.5527/wjn.v14.i4.109457] |
|---|---|
| URL: | https://www.wjgnet.com/2220-6124/full/v14/i4/109457.htm |
| Number | Citing Articles |
| 1 |
Vanishri Ganakumar, Cornelius J Fernandez, Joseph M Pappachan. Glucagon-like peptide-1 receptor agonists in type 2 diabetes: Evidence for disease modification and therapeutic switching. World Journal of Diabetes 2026; 17(6): 116477 doi: 10.4239/wjd.116477
|
| 2 |
Karina Kofman, Aviv Ouanounou. Oral Health Considerations and Dental Management Guidelines for Semaglutide Medications. Canadian Journal of Diabetes 2026; 50(6) doi: 10.1016/j.jcjd.2026.03.008
|
| 3 |
Wang Long. Short-Term Comparative Effects Of Semaglutide, Either Alone Or In Conjunction With Canagliflozin, On Early Diabetic Kidney Disease. Pakistan Journal of Pharmaceutical Sciences 2026; doi: 10.36721/PJPS.2026.39.7.204.1
|
| 4 |
Eugenia Pedagogos, Roger Chen, Adam Nelson, Sunil Badve, Roy Rasalam, Richard MacIsaac. Semaglutide in type 2 diabetes and chronic kidney disease in Australia: practical clinical considerations from a multidisciplinary panel. Internal Medicine Journal 2026; doi: 10.1111/imj.70647
|